These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
529 related articles for article (PubMed ID: 10807047)
1. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives. Neurath MF Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047 [TBL] [Abstract][Full Text] [Related]
2. Gene transfer approaches for the treatment of inflammatory bowel disease. Wirtz S; Neurath MF Gene Ther; 2003 May; 10(10):854-60. PubMed ID: 12732871 [TBL] [Abstract][Full Text] [Related]
3. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Sartor RB Gastroenterol Clin North Am; 1995 Sep; 24(3):475-507. PubMed ID: 8809232 [TBL] [Abstract][Full Text] [Related]
4. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Sartor RB Am J Gastroenterol; 1997 Dec; 92(12 Suppl):5S-11S. PubMed ID: 9395346 [TBL] [Abstract][Full Text] [Related]
5. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD). Heresbach D; Sémana G; Gosselin M; Bretagne MG Eur Cytokine Netw; 1999 Mar; 10(1):7-15. PubMed ID: 10210767 [TBL] [Abstract][Full Text] [Related]
8. Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Dieleman LA; Peña AS; Meuwissen SG; van Rees EP Scand J Gastroenterol Suppl; 1997; 223():99-104. PubMed ID: 9200314 [TBL] [Abstract][Full Text] [Related]
9. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. Hibi T; Inoue N; Ogata H; Naganuma M J Gastroenterol; 2003 Mar; 38 Suppl 15():36-42. PubMed ID: 12698869 [TBL] [Abstract][Full Text] [Related]
11. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis. Agius LM J Theor Biol; 2004 Mar; 227(2):219-28. PubMed ID: 14990386 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases. Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080 [TBL] [Abstract][Full Text] [Related]
13. Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. Fiocchi C Minerva Gastroenterol Dietol; 2002 Sep; 48(3):215-26. PubMed ID: 16491045 [TBL] [Abstract][Full Text] [Related]
14. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Leach MW; Bean AG; Mauze S; Coffman RL; Powrie F Am J Pathol; 1996 May; 148(5):1503-15. PubMed ID: 8623920 [TBL] [Abstract][Full Text] [Related]
15. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms. Dignass AU; Baumgart DC; Sturm A Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():9-17. PubMed ID: 15352888 [TBL] [Abstract][Full Text] [Related]
16. Signaling for inflammation and repair in inflammatory bowel disease. Neuman MG Rom J Gastroenterol; 2004 Dec; 13(4):309-16. PubMed ID: 15624029 [TBL] [Abstract][Full Text] [Related]
17. New therapies for inflammatory bowel disease: from the bench to the bedside. Danese S Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827 [TBL] [Abstract][Full Text] [Related]
18. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Reuter BK; Pizarro TT Eur J Immunol; 2004 Sep; 34(9):2347-55. PubMed ID: 15307167 [TBL] [Abstract][Full Text] [Related]